News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AIBioTech Receives Subcontract Award From DynPort Vaccine Company LLC, for Continued Development and FDA Approval of a Nerve Agent Prophylactic


5/23/2013 9:33:02 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

RICHMOND, Va., May 23, 2013 (GLOBE NEWSWIRE) -- AIBioTech is pleased to announce receipt of a firm fixed price subcontract from DynPort Vaccine Company LLC (DVC), a CSC company, valued at nearly $3 million for laboratory studies to support development of a biologic intended for use prior to an exposure to nerve agents. DVC issued this subcontract under its prime contract number W911QY-13-C-0056 with the U.S. Department of Defense.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   
Vaccine

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES